QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

XERS

QT76Xeris Biopharma Holdings, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
6.95
+0.05+0.72%
OverviewShort InterestFilings
XERSQT76Xeris Biopharma Holdings, Inc.·NASDAQ
OverviewShort InterestFilings
6.95+0.72%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E97.99EPS (ttm)
0.07
Insider Own11.69%
Shs Outstand172.64M
Perf Week0.29%
Market Cap1.19BForward P/E18.89EPS next Y0.37Insider Trans-0.03%Shs Float-Perf Month17.40%
Enterprise Value1.12BPEG0.01EPS next Q0.02Inst Own-Short Float-Perf Quarter24.55%
Income12.15MP/S3.78EPS this Y107.34%Inst Trans-Short Ratio-Perf Half Y-2.11%
Sales314.85MP/B90.43EPS next Y153.45%ROA3.06%Short Interest-Perf YTD-11.46%
Book/sh0.08P/C24.25EPS next 5Y66.67%ROE735.00%52W High10.08 -31.05%Perf Year53.08%
Cash/sh0.65P/FCF25.22EPS past 3/5Y-ROIC12.84%52W Low4.40 57.95%Perf 3Y-
Dividend Est.-EV/EBITDA24.21Sales past 3/5Y38.46% 70.95%Gross Margin81.59%Volatility1.96% 2.63%Perf 5Y-
Dividend TTM-EV/Sales3.55EPS Y/Y TTM117.16%Oper. Margin11.40%ATR (14)0.25Perf 10Y-
Dividend Ex-Date-Quick Ratio1.50Sales Y/Y TTM55.17%Profit Margin3.81%RSI (14)65.65Recom2.10
Dividend Gr. 3/5Y-Current Ratio2.12EPS Q/Q116.67%SMA208.06%Beta0.91Target Price8.82
Payout0.00%Debt/Eq2.87Sales Q/Q38.33%SMA5010.76%Rel Volume1.48Prev Close6.90
Employees394LT Debt/Eq2.29EarningsAug 06SMA200-1.30%Avg Volume1.61MPrice6.95
IPO DateJun 21, 2018Option/ShortYes / YesEPS/Sales Surpr.464.96% 2.50%Net Debt/EBITDA-1.61Volume2,383,430Change0.72%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-08-25InitiatedBarclaysOverweight$9.00
Oct-29-25ReiteratedOppenheimerOutperform$5.00 → $18
Mar-07-25ReiteratedPiper SandlerNeutral$3.00 → $4.00
Nov-11-24ReiteratedH.C. Wainwright$6.60
Nov-11-24DowngradePiper SandlerOverweight → Neutral
Oct-23-24ReiteratedOppenheimer$5.00
May-10-24ReiteratedPiper SandlerOverweight$3.00
Apr-28-22ReiteratedCraig-HallumBuy$6.50
Latest News
Jun-11-26
Jun-11-2604:40PM
Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of UseBenzinga
07:09AM
Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of SharesBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue315292203
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A585337
Gross Profit257238166
Selling, General and Administrative Excl. Other191182163
Research and Development323126
Other Operating Expense-2111
Operating Income3625-34
Interest Expense282933
Unusual Expense
———
Non-Operating Income (Expense)324-7
Net Income Before Taxes121-57
Income Taxes00-2
Consolidated Net Income121-55
Net Income From Continuing Operations121-55
Net Income121-55
EPS (Recurring)0.070.00-0.37
EPS (Basic, Before Extraordinaries)0.070.00-0.37
EPS (Diluted)0.070.00-0.37
EBITDA4613-14
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio99.292,453.12—
Price To Sales Ratio3.774.30—
Gross Margin81.5981.5181.77
Operating Margin11.438.56-16.75
Net Margin3.810.34-27.09
Shares Outstanding171160147
Market Capitalization1,1881,256—
Operating Lease Expense
———
Insider Trading Volume
$7.37$6.63$5.89$5.15$4.41● Close Price0.00M0.36M0.72M1.07M1.43MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HALKUFF DAWNDirectorJun 04 '26Sale6.0920,000121,88695,000Jun 05 12:00 AM
BORMANN-KENNEDY BARBARA-JEAN ANNEDirectorJun 04 '26Sale6.0916,00097,507126,500Jun 05 12:00 AM
JOHNSON JOHNDirectorJun 04 '26Sale6.0915,00091,422683,083Jun 05 12:00 AM
PERSKY MARLADirectorJun 03 '26Sale5.9015,50091,433126,500Jun 05 12:00 AM
Hecht BethSee RemarksJun 01 '26Sale6.0616,667100,9821,176,506Jun 02 12:00 AM
Hecht BethSee RemarksMay 01 '26Sale6.2316,667103,8051,193,173May 01 12:00 AM
Hecht BethSee RemarksApr 01 '26Sale5.9916,66799,8591,209,840Apr 03 12:00 AM
Brady James AloysiusDirectorMar 30 '26Sale5.5410,83460,03689,166Apr 01 12:00 AM
McCulloch KevinSee RemarksMar 12 '26Option Exercise4.0997,796399,9841,777,725Mar 16 12:00 AM
Pieper StevenSee RemarksMar 05 '26Option Exercise4.7183,854394,6141,408,940Mar 05 12:00 AM
Hecht BethSee RemarksMar 02 '26Sale6.2516,667104,0861,226,507Mar 04 12:00 AM
Hecht BethSee RemarksFeb 02 '26Sale7.4516,667124,1471,243,174Feb 02 12:00 AM
McCulloch KevinSee RemarksJan 08 '26Sale8.0015,000120,0001,685,426Jan 09 12:00 AM
Shannon John Patrick JrSee RemarksJan 05 '26Option Exercise1.67120,337200,3852,797,647Jan 06 12:00 AM
Shannon John Patrick JrSee RemarksJan 05 '26Sale7.0824,907176,2572,705,346Jan 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR